Rhabdomyosarcoma Review 2017:

Children’s Oncology Group

Luke E. Pater MD, John Breneman MD, Suzanne Wolden MD and Sarah Donaldson MD
Outline
• Epidemiology
• Patterns of Involvement
• Pathology
• Staging
• Clinical Evaluation and Work-up
• Treatment
• Results of Treatment
• Significant Clinical Trials
• Complications of Treatment
Outline
• Epidemiology
• Patterns of Involvement
• Pathology
• Staging
• Clinical Evaluation and Work-up
• Treatment
• Results of Treatment
• Significant Clinical Trials
• Complications of Treatment
Epidemiology
• Accounts for 3% of childhood cancers and 2% of adolescent
cancers
• Embryonal RMS (approximately 50% of cases): incidence is
highest in children aged younger than 5 years
• Alveolar RMS (approximately 40% of cases): incidence does
not vary by age in children and adolescents
Adult & Pediatric Rhabdomyosarcoma SEER 1973 - 2005

Sultan, I, JCO 27: 2009

Outline
• Epidemiology
• Patterns of Involvement
• Pathology
• Staging
• Clinical Evaluation and Work-up
• Treatment
• Results of Treatment
• Significant Clinical Trials
• Complications of Treatment
Distribution of Sites
Orbit
Parameningeal
Head/Neck
9%
16%
10%

Other 22% 24%

GU

19%

Extremity
Sites of Metastatic Involvement
(IRS-IV)
Lung 39%
Bone Marrow 32%
Lymph Nodes 30%
Bone 27%
Omentum/Ascites 16%
Soft Tissue 16%
Outline
• Epidemiology
• Patterns of Involvement
• Pathology
• Staging
• Clinical Evaluation and Work-up
• Treatment
• Results of Treatment
• Significant Clinical Trials
• Complications of Treatment
Pathology

•Accurate pathology requires:

1) H and E
2) Immunohistochemistry
3) Molecular genetics
 Embryonal Rhabdomyosarcoma (Botryoid)

www.pedsoncologyeducation.com

Botryoid ERMS is a less common variant of embryonal RMS with improved prognosis.
Most commonly arises from mucosal surfaces of the vagina, bladder, uterus, bile duct,
nasopharynx and middle ear. These tumors are generally localized and non-invasive
and have a grape like configuration macroscopically.
 Embryonal Rhabdomyosarcoma

Medscape.com
Embryonal rhabdomyosarcoma is evidenced by a variable cell population consisting of small,
round tumor cells with hyperchromatic nuclei and of large, polygonal-shaped tumor cells
with abundant eosinophilic cytoplasm, which often contains diagnostic cross striations.
 Alveolar Rhabdomyosarcoma

Medscape.com
Alveolar rhabdomyosarcoma is evidenced by uniform cell population consisting of cells
with a high nuclear-to-cytoplasmic ratio. The cells are arranged in variably sized nests
separated by fibrous tissue septa. In places, the cells appear loosely dispersed, mimicking
a pulmonary alveolar pattern.
Molecular Genetics of RMS
Embryonal RMS
• Loss of heterozygosity at 11p15 locus
• Location of the IGF-II gene

Alveolar RMS
• t(2;13)(q35;q14)
‒ Translocation between long arms of chr 2 and 13 fusing
FOX01 transcription factor to PAX3
• t(1;13)(p36;q14)
‒ Fuses FOX01 to PAX7
Risk Stratification Gene Expression Status

ALVn

ALVn
EMB

EMB

ALVp ALVp

• Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly

indistinguishable from embryonal rhabdomyosarcoma.
• Fusion gene status is useful in risk stratification.

Williamson, JCO, 2010

 PAX / FOXO1 predicts outcome
D9803- Intermediate Risk RMS
Event-free Survival, D9803 (Stage 2/3, Group III)
by fusion status (reclassified ERMS included in ERMS)
(ERMS not reviewed included)

1.0

0.9
ARMSn (n=11)
0.8
ERMS (n=261)
Event Free Survival

0.7

0.6 PAX7 (n=11)

Proportion

0.5

0.4 PAX3 (n=57)

Test: p<0.001

0.3

0.2
P<0.001
0.1 n = 340
0.0

0 2 4 6 8 10

Time
dxx3 CENSOR FAIL TOTAL MEDIAN
ARMSPAX3 29 28 57 2.96 Skapek S, Pediatr Blood Cancer, 2013
ARMSPAX7 6 5 11 .
ARMSneg 9 2 11 .
ERMS 198 63 261 .
IRS V - Pathology
Outline
• Epidemiology
• Patterns of Involvement
• Pathology
• Staging
• Clinical Evaluation and Work-up
• Treatment
• Results of Treatment
• Significant Clinical Trials
• Complications of Treatment
TNM Staging
• T1 – Confined to site of origin
• T2 – Invasive into surrounding tissues
• a - <5 cm in size
• b - >5 cm in size

• N0 – No involved regional nodes

• N1 – Regional nodes are involved
 Staging
Stage Site* Invasiveness Size Nodal status Mets

I Favorable T1 or T2 a or b N0 or N1 M0
II Unfavorable T1 or T2 a N0 M0
III Unfavorable T1 or T2 b N0 M0
a or b N1 M0
IV Any site T1 or T2 N0 or N1 M1

Favorable sites: orbit, head and neck (non-parameningeal), genitourinary (non–bladder-prostate);

Unfavorable sites: genitourinary (bladder-prostate), extremity, parameningeal, other.
Group I Localized disease, completely resected
A Confined to organ or muscle of origin

B Infiltration outside organ or muscle of origin; regional nodes not involved

Group II Compromised or regional resection

A Grossly resected tumor with microscopic residual disease

B Regional disease, completely resected, in which nodes may be involved or

extension of tumor into adjacent organ may exist

C Regional disease with involved nodes, grossly resected, but with evidence of
microscopic residual disease

Group III Incomplete resection or biopsy with gross residual disease

Group IV Distant metastases at diagnosis

Outline
• Epidemiology
• Patterns of Involvement
• Pathology
• Staging
• Clinical Evaluation and Work-up
• Treatment
• Results of Treatment
• Significant Clinical Trials
• Complications of Treatment
Clinical Evaluation and Work-up
• Laboratory Studies:
• CBC
• Liver function tests
• Renal function tests
• Urinalysis (UA)
• Blood electrolyte and chemistry
Clinical Evaluation and Work-up

• Imaging Studies:
• Plain radiography: Radiography of the primary site and of the chest is
helpful in determining the presence of calcifications and bone involvement
of the primary tumor and to search for metastatic lung lesions.
• CT Chest
• CT or US of the liver
• CT or MRI of primary site, pending location
• Bone scan or PETCT for metastatic assessment
• Echocardiography: Assess cardiac function before chemotherapy
Clinical Evaluation and Work-up

• Procedures:
• Biopsy: Open biopsy preferred, resection typically reserved for post-
chemotherapy administration
• Cytogenetics, fluorescent in situ hybridization (FISH)
• Reverse transcriptase–polymerase chain reaction (RT-PCR) testing when
cytogenetic testing is unavailable
• Bone marrow aspiration and biopsy
Outline
• Epidemiology
• Patterns of Involvement
• Pathology
• Staging
• Clinical Evaluation and Work-up
• Treatment
• Results of Treatment
• Significant Clinical Trials
• Complications of Treatment
Survival in Rhabdomyosarcoma Four Decades of Progress

IRS-V
IRS-IV
IRS-III
IRS-II
IRS-I

Pre
Cooperative
Group
The Intergroup Rhabdomyosarcoma Study-I: A Final Report
MAURER H, BELTANGADY M, GEHAN E, et al. Cancer 61: 209-220, 1988
The Intergroup Rhabdomyosarcoma Study-I: A Final Report
MAURER H, BELTANGADY M, GEHAN E, et al. Cancer 61: 209-220, 1988

Conclusions:

1) Clinical Group I:
1) 5y DFS 80% and 5y OS 83%
2) Addition of postoperative RT to VAC chemotherapy provided no advantage

2) Clinical Group II:

1) 5y DFS 65% and 5y OS 70%
2) Adding cyclophosphamide (oral) to vincristine/dactinomycin did not result in any significant improvement

3) Clinical Groups III/IV

1) CR in group III was 69% and group IV 50% with no difference between arms
2) 5y OS 52% in group III and 20% in group IV, no difference between arms
The Intergroup Rhabdomyosarcoma Study II
Maurer H, Gehan E, Beltangady M, et al. CANCER 71(5) 1904-22, 1993
The Intergroup Rhabdomyosarcoma Study II
Maurer H, Gehan E, Beltangady M, et al. CANCER 71(5) 1904-22, 1993

Conclusions:

1) Cyclophosphamide did not contribute to the success of treatment in Clinical Groups I and II patients
(extremity alveolar patients excluded)

2) Repetitive-pulse chemotherapy for 2 years increased survival rates in children with Group III but
not IV disease

3) Adriamycin offered no advantage over dactinomycin and was associated with more fatal toxicities

4) Approach to treating patients with parameningeal sarcoma used in IRS-II, including compliance
with radiation dose and volume and earlier timing, was successful in preventing CNS
recurrence and increased survival rates

5) Treatment of "special" pelvic tumors with primary repetitive-pulse VAC primary chemotherapy did
not result in durable bladder salvage, although survival rate was not compromised

6) There was some indication that repetitive-pulse VAC chemotherapy improved the prognosis of
patients with Clinical Groups I and I1 extremity alveolar rhabdomyosarcoma
The Intergroup Rhabdomyosarcoma Study II
Maurer H, Gehan E, Beltangady M, et al. CANCER 71(5) 1904-22, 1993

Local Control of ~90% in groups II-IV (regimens 23-29 contain RT)

The Third Intergroup Rhabdomyosarcoma Study
Crist W, Gehan E, Abdelsalam R, et al. J Clin Oncol 13:610-630, 1995
The Third Intergroup Rhabdomyosarcoma Study
Crist W, Gehan E, Abdelsalam R, et al. J Clin Oncol 13:610-630, 1995

Conclusions:

1) 5y survival estimate increased by 8% compared with IRS-II (71% 2% v 63% ± 2%) and by 16%
(71% ± 2% v 55% ± 2%) compared with the result for IRS-I.
- improved therapy for patients with group III tumors, except for selected head and
orbit sites and those with group I or II alveolar tumors

2) Patients with favorable-histology tumors in an orbital or a nonparameningeal head site, in clinical

group I, II, or III, responded as well to cyclic sequential, thus, it should be possible to delete this
alkylating agent from future protocols

3) Therapy for children with RMS should be risk-directed and based primarily on tumor site and the
extent of disease
- limited-stage tumors (group I or II) generally respond well to surgery, VA
chemotherapy, and RT (group II only)
- All other patients seem to require more intensive multimodality therapy
- We believe that chemotherapy of increased dose intensity, with concomitant use of
hematopoietic growth factors, should be further exploited to improve cure
rates for patients with moderate or high-risk RMS
Intergroup Rhabdomyosarcoma Study-IV: Results for Patients With Nonmetastatic Disease
Crist W, Anderson J, Meza J, et al. J Clin Oncol 9: 3091-3102, 2001
Intergroup Rhabdomyosarcoma Study-IV: Results for Patients With Nonmetastatic Disease
Crist W, Anderson J, Meza J, et al. J Clin Oncol 9: 3091-3102, 2001

Conclusions:

1) 3y FFS estimates remain unchanged, despite use of intensive, multimodal therapy, from that of IRS-III (~76%)

2) Patients with local or regional tumors with embryonal histology fared significantly better on VAC, VAI, or VIE
plus surgery and RT than did similar patients treated on IRS-III (3-year FFS
rates, 83% v 74%).
-Improvement seemed to be restricted to patients with stage I/II, group 1/2 disease,
many of whom received VA chemotherapy on IRS-III
-Majority of the improvement is probably attributable to the addition of alkylating agent to
the therapy received by patients treated on IRS-IV, although changes in RT,
surgery, and/or supportive care may have played a role

3) Therapy for pediatric RMS should be risk-directed and based primarily on tumor site, tumor history, and
extent of disease

4) Group III patients randomized to standard fractionation versus hyperfractionated RT, statistically equivalent
Intergroup Rhabdomyosarcoma Study-IV: Results for Patients With Nonmetastatic Disease
Crist W, Anderson J, Meza J, et al. J Clin Oncol 9: 3091-3102, 2001

Conclusions:

5) Younger patients (<10 years old) with embryonal, group 1 tumors arising in the paratestis fared well with
surgery and VA chemotherapy, whereas similar adolescents require more accurate staging with
retroperitoneal LN dissection, followed by RT and VAC chemotherapy for those with group 2 tumors

6) Group 2/3 orbit or eyelid tumors generally fare well with surgery + VA chemotherapy (group 1) or surgery +
RT + VA chemotherapy (group 2).

7) Most other patients appear to require more intensive multimodality therapy, and the relatively poor outcome
for some patient subsets indicates that new therapeutic approaches, including effective new agents,
are required (Topotecan is the most promising new agent for rhabdomyosarcoma)

8) Infants and adolescents have worse outcome than do children with rhabdomyosarcoma, perhaps due in
part to their higher frequency of undifferentiated or alveolar histiotypes and thus may especially
benefit from this new approach
Results of the Intergroup Rhabdomyosarcoma Study Group D9602 Protocol
Raney B, Walterhouse D, Meza J, et al. J Clin Oncol 29: 1312-1318, 2011

Purpose:
•ERMS patients with localized, grossly resected, or gross residual (orbital only) disease have good 5y
FFS (83%) and OS (95%)

•Objectives were to decrease toxicity in similar patients by reducing RT and eliminating

cyclophosphamide for the lowest-risk patients

Patients and Methods

•Subgroup A (lowest risk, ERMS, stage 1 group I/IIA, stage 1 group III orbit, stage 2 group I):
-vincristine plus dactinomycin (VA)
•Subgroup B (ERMS, stage 1 group IIB/C, stage I group III nonorbit, stage 2 group II, stage 3 group I/II):
-VA plus cyclophosphamide
•Patients in group II/III received RT:
-Compared with IRS-IV: Stage 1 group IIA reduced from 41.4 to 36 Gy and group III orbit from
50 or 59 to 45 Gy
Results of the Intergroup Rhabdomyosarcoma Study Group D9602 Protocol
Raney B, Walterhouse D, Meza J, et al. J Clin Oncol 29: 1312-1318, 2011

Conclusions:
1) 5y FFS rates were 89% for subgroup A and 85% for subgroup B

2) 5y FFS rates were 81% for stage 1 group IIA and 86% forgroup III orbit tumors

3) These rates were similar to those observed in comparable IRS-III patients, including
patients receiving reduced RT doses, but were lower than in comparable IRS-
IV patients receiving VA plus cyclophosphamide
Shorter-Duration Therapy Using Vincristine, Dactinomycin, and Lower-Dose Cyclophosphamide With or Without
Radiotherapy for Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma: A Report From the Soft Tissue Sarcoma
Committee of the Children’s Oncology Group (ARST0331)
Walterhouse D, Pappo J, Meza J, et al. J Clin Oncol 32: 3547-3552, 2014

Purpose

•IRSG III and IV showed improved FFS with VAC over VA for patients with stage 1/2 group I/II
ERMS or stage 1 group III orbit ERMS
•Objective of Children’s Oncology Group ARST0331 was to reduce the length of therapy
without compromising FFS for this subset of low-risk patients using VA in combination
with lower-dose cyclophosphamide (total cumulative dose, 4.8 g/m2) plus radiotherapy
Shorter-Duration Therapy Using Vincristine, Dactinomycin, and Lower-Dose Cyclophosphamide With or Without
Radiotherapy for Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma: A Report From the Soft Tissue Sarcoma
Committee of the Children’s Oncology Group (ARST0331)
Walterhouse D, Pappo J, Meza J, et al. J Clin Oncol 32: 3547-3552, 2014

Conclusions

1) Shorter-duration therapy that included lower-dose cyclophosphamide and RT did not

compromise FFS for patients with subset-one low-risk ERMS

2) 3y FFS 89% and OS 98%

3) Patients with paratesticular tumors had the most favorable outcome

4) 3y cumulative incidence rates for any local, regional, or distant failures were 7.6%, 1.5%, and
3.4%, respectively.
Local therapy is critical in localised pelvic rhabdomyosarcoma: Experience of the International Society of Pediatric Oncology
Malignant Mesenchymal Tumor (SIOP-MMT) committee
Re’guerre Y, Martelli H, Rey A, et al. European Journal of Cancer 48: 2020–2027, 2012

Purpose:
• Localized pelvic rhabdomyosarcomas (pRMS) are rare tumours with a poorer prognosis than
the majority of RMS
• This study analyzed patient outcome according to the type of local therapy delivered and the
effect of disease-related factors on prognosis
Local therapy is critical in localised pelvic rhabdomyosarcoma: Experience of the International Society of Pediatric Oncology
Malignant Mesenchymal Tumor (SIOP-MMT) committee
Re’guerre Y, Martelli H, Rey A, et al. European Journal of Cancer 48: 2020–2027, 2012
Local therapy is critical in localised pelvic rhabdomyosarcoma: Experience of the International Society of Pediatric Oncology
Malignant Mesenchymal Tumor (SIOP-MMT) committee
Re’guerre Y, Martelli H, Rey A, et al. European Journal of Cancer 48: 2020–2027, 2012
Local therapy is critical in localised pelvic rhabdomyosarcoma: Experience of the International Society of Pediatric Oncology
Malignant Mesenchymal Tumor (SIOP-MMT) committee
Re’guerre Y, Martelli H, Rey A, et al. European Journal of Cancer 48: 2020–2027, 2012

Conclusions:
1) 87 patients achieved local control (90%), 37 relapsed (43%), mainly locally (84%)

2) 5y OS was 66% and EFS was 52%

3) In multivariate analysis, IRS staging, age greater than 10 years and lymph node involvement had
a negative impact on OS

4) Perineal/perianal locations had a trend towards a worse prognosis

5) Radiotherapy or brachytherapy is necessary for all IRS-III patients including those with
radiological complete remission after neoadjuvant chemotherapy with or without surgery

6) Radiotherapy may be withheld in IRS-I patients and children under 3 years with IRS-II pRMS
Local Control for Intermediate-Risk Rhabdomyosarcoma: Results From D9803 According to
Histology, Group, Site, and Size: A Report From the Children’s Oncology Group
Wolden S, Lyden E, Arndt C, et al. Int J Radiat Oncol Biol Phys 93(5): 1071–1076 , 2015

Objective:

• Determine local control according to clinical variables for patients with intermediate-risk
rhabdomyosarcoma (RMS) treated on Children’s Oncology Group protocol D9803.

Patients and Methods:

• 702 patients enrolled, 423 patients analyzed

• 280 group III embryonal, 102 group III alveolar and 41 group I-II alveolar

• Patients received 42 weeks of VAC (vincristine, dactinomycin, cyclophosphamide) or VAC

alternating with VTC (T = topotecan)

• Group III: 50.4 Gy radiation therapy with or without delayed primary excision began at week 12

• Group I/II alveolar RMS received 36–41.4 Gy

Local Control for Intermediate-Risk Rhabdomyosarcoma: Results From D9803 According to
Histology, Group, Site, and Size: A Report From the Children’s Oncology Group
Wolden S, Lyden E, Arndt C, et al. Int J Radiat Oncol Biol Phys 93(5): 1071–1076, 2015

Conclusions:

• Group I/II alveolar RMS:

• 5y EFS 69% and LF of 10%

• Group III RMS:

• 5y EFS 70% and LF of 19%

• Local failure rates did not differ by histology, nodal status, or primary site

• Trend for increased LF for retroperitoneal tumors (P = .12)

• Tumors ≥5 cm were more likely to fail locally than tumors <5 cm (25% vs 10%, P = .0004)
• Almost all (98%) RP tumors were ≥5 cm, with no difference in LF by site when the analysis
was restricted to tumors ≥5 cm (P = .86)
ARST1431 Study Design
RT
VAC/VI week VAC/VI
13

R
RT
VAC/VI VAC /VI
week
+TEM* 13
+TEM*

*Temsirolimus:
mTOR inhibitor
FDG-PET optional – week 1, 9, 30
 Guidelines for ARST 1431

• All primary site RT at week 13

• Protocol recommends rad onc consultation at diagnosis
to assess imaging, credentialing, etc
• No early RT for high risk parameningeal tumors
• Emergent RT only in rare case of failure to respond to
chemotherapy
• Protons, IMRT, 3D and brachytherapy allowed
• Expect 50:50 proton and IMRT
 D9803: Local failure Group III by size
Cumulative incidence of any local failure,D9803 Group III (N=382)
atbydiagnosis
tumor size

0.30

0.25

>= 5 cm 25%
Proportion Local Failures

0.20

0.15

< 5 cm 10%
0.10

0.05
p=0.0004
Log-Rank, p=0.0004

0.00

0 2 4 6 8 10

Years

xsize < 5 cm => 5 cm

 Guidelines for ARST 1431

• Dose escalation to 59.4 Gy mandatory for tumors

>5cm at study entry (not at time of RT)
• Cone-down at 36 Gy to residual gross disease
• If no reduction in size, no cone-down
• In rare case of CR, total dose will be 36 Gy
• Must be no residual abnormality on CT/MRI AND
• Negative PET OR negative biopsy to confirm
• If DPE, 36 Gy if margins neg, 41.4 if positive
 Role of PET scans on 1431

• PET scans encouraged but not mandated

• Reduction in RT dose to 36 in cases of CR
• Requires complete resolution of tumor on CT/MRI
• Additional requirement that biopsy be negative OR PET
be negative is redundant and primarily an inducement to
do PET scans
• PET response and outcomes will be studied but in
practice, PET response is not impacting treatment
on ARST1431
 Dose to primary tumor: ARST 1431
Clinical no CR at CR at Week post DPE with post DPE with post DPE, gross
Group Week 9** 9** negative microscopic residual disease
margin margin
I, FOXO1 + 36 36 N/A N/A N/A

II 36 36 N/A N/A N/A

III, ≤5cm* 50.4 36 36 41.4 50.4

III, >5cm* 59.4 36 36 41.4 59.4

*Based on size at diagnosis

**CR defined as 1) Radiological CR by both PET and CT/MRI or 2) biopsy that shows no
residual tumor.
 Patients < 24 months old

• Adherence to guidelines is encouraged

• Outcome was poorer for these patients on 0531
• Deviation allowed only for children < 24 months
who are FOXO1 negative
• Will be noted as “variation” but not formal “deviation”
• Rationale and treatment must be submitted to IROC
 Optional SBRT for bone mets <5cm: ARST 1431

Bone mets in SD/PR

Dose/fraction (Gy) Dose (Gy)
PTV2 =GTV2 7.0 35
PTV1= CTV2 + 2mm 6.0 24
After 15Gy whole lung
PTV2 = GTV2 6.0 30
PTV1 = CTV2+2mm 5.0 25

Bone mets in CR
PTV2 =GTV2 6.0 30
PTV1= CTV2 + 2mm 5.0 25
After 15Gy whole lung
PTV2 = GTV2 5.0 30
PTV1 = CTV2+2mm 4.0 20
 RT Volume Guidelines
Group III
• IRS I Involved muscle compartment
• IRS II Initial tumor volume + 5 cm
• IRS III Initial tumor volume + 5 cm
• IRS IV Initial tumor volume + 2 cm
• IRS V 3D – CRT to GTV + 1.5 cm CTV + 0.5 cm PTV
• Current IMRT to GTV + 1.0 cm CTV + 0.3 cm PTV
Outline
• Epidemiology
• Patterns of Involvement
• Pathology
• Staging
• Clinical Evaluation and Work-up
• Treatment
• Results of Treatment
• Significant Clinical Trials
• Complications of Treatment
Preliminary Results of a Phase II Trial of Proton Radiotherapy for Pediatric Rhabdomyosarcoma
Ladra M, Szymonifka J, Mahajan A, et al. J Clin Oncol 32:3762-3770, 2014

Prospective phase II study:

• 57 pediatric patients with localized RMS or metastatic embryonal RMS enrolled between
February 2005 and August 2012

• All patients were treated with chemotherapy (vincristine, actinomycin, and cyclophosphamide
or vincristine, actinomycin, and ifosfamide–based) and proton
Preliminary Results of a Phase II Trial of Proton Radiotherapy for Pediatric Rhabdomyosarcoma
Ladra M, Szymonifka J, Mahajan A, et al. J Clin Oncol 32:3762-3770, 2014

Conclusions:

• 5y EFS 69%, OS 78% and LC 81%

• 5y LC by risk-group: Low-risk 93% and high-risk 77%

• 5y LC, EFS, and OS rates were similar to those observed in comparable trials with photon RT

• Acute and late toxicity rates were favorable:

• 13 patients with grade 3 acute toxicity

• 3 patients with grade 3 late toxicity
• No acute or late toxicities higher than grade 3
Tumour control and Quality of Life in children with rhabdomyosarcoma treated with pencil beam scanning proton therapy
Leiser D, Calaminus G, Malyapa R, et al. Radiotherapy and Oncology 120:163–168, 2016

Objective:

• To assess clinical outcomes in children with RMS treated with pencil beam scanning proton therapy

Methods and materials:

• 83 RMS (89% embryonal) patients treated between January 2000 and December 2014 included

• All received systemic chemotherapy according to prospective protocols

• Low-risk 27%, intermediate-risk 63%, andhigh-risk13% of cases, respectively

• Median total dose delivered was 54 Gy(RBE) (range, 41.4–64.8

Tumour control and Quality of Life in children with rhabdomyosarcoma treated with pencil beam scanning proton therapy
Leiser D, Calaminus G, Malyapa R, et al. Radiotherapy and Oncology 120:163–168, 2016
Tumour control and Quality of Life in children with rhabdomyosarcoma treated with pencil beam scanning proton therapy
Leiser D, Calaminus G, Malyapa R, et al. Radiotherapy and Oncology 120:163–168, 2016
Tumour control and Quality of Life in children with rhabdomyosarcoma treated with pencil beam scanning proton therapy
Leiser D, Calaminus G, Malyapa R, et al. Radiotherapy and Oncology 120:163–168, 2016

Conclusions:

• 5y LC 78.5% and OS 80.6%

• 5y incidence of grade 3 non-ocular late toxicity was 3.6%

• No grade 4–5 late toxicities observed

• One radiation-induced malignancy (1.2%)

• QoL scores increased significantly after PT compared to baseline

Clinical Case 1:
28 year old female with stage 3, group III spindle cell rhabdomyosarcoma of the right upper extremity s/p chemotherapy per
ARST0531, Regimen A and s/p wide local excision with full thickness skin graft. Patient was noted to have 65% viable tumor
and tumor was present within 2mm of the deep resection margin.
Clinical Case :
21 year old female with a parameningeal spindle cell rhabdomyosarcoma of left face, stage 3, group 3 s/p VAC chemotherapy
as per ARST 0531 Group B, with progression of disease despite chemotherapy. Her chemotherapy was transitioned to VDC as
per ARST0431.
Clinical Case 3:
4 year old female with a biliary tree ERMS, stage 1, group III. Slow initial response to chemotherapy.
Conclusions

• Significant improvements in outcomes over past several decades

• Local control remains significant risk

• Improved understanding of risk factors now guiding treatment

• Treatment related toxicity modified by dose deescalation when feasible

and improved radiotherapy delivery